Education ▼

PER is hosting the 2nd Annual International Congress on Oncology Pathology^™ | June 23rd in NYC Hematologic Malignancies Medical Crossfire in NYC on July 14th! Register today!

SPECIALTY TOPICS

CURRENTLY VIEWING
Hematologic Oncology

Gastrointestinal Cancer

Hematologic Oncology

Ruxolitinib Reaches 55% Response Rate in Pivotal GVHD Trial

Ruxolitinib combined with corticosteroids induced an overall response rate of 55% at day 28 in patients with steroid-refractory acute graft-versus-host disease, meeting the primary endpoint of the phase II REACH1 trial.
Read More >>

Expert Discusses Venetoclax Potential in MCL

Blinatumomab Granted Full EU Approval for B-cell Precursor ALL

Novel Targeted Antibody-Drug Conjugates in Non-Hodgkin Lymphoma

2018 EHA: Elotuzumab/Pomalidomide Prolongs PFS in Pretreated Multiple Myeloma

2018 EHA: Upfront Duvelisib Plus FCR Shows Promise in Younger Patients With CLL

View More Stories >>

View Conference Coverage

2018 World Congress on GI Cancer

2018 European Hematology Association Congress

2018 State of the Science Summit on Genitourinary Cancers

2018 ASCO Annual Meeting

2018 ASPHO Conference

Dr. Richardson Discusses the Results of the OPTIMISMM Trial in Myeloma

Dr. Pecora on the Role of Stem Cell Transplant in Patients With Multiple Myeloma

Dr. Goy on Prognostic Markers in Mantle Cell Lymphoma

$Dr. Davids Discusses Duvelisib in Relapsed/Refractory CLL$

Dr. Biran on Patient-Reported Outcomes Following Transplant in Multiple Myeloma

Dr. Wang Discusses the ZUMA-2 Trial in Mantle Cell Lymphoma

Dr. Usmani Discusses Immunotherapy in Hematologic Malignancies

OncLive houses thousands of videos that provide updates and information.
See more Videos

Future Direction for Polycythemia Vera

PV: Treatment With Ruxolitinib

Rationale for JAK Inhibition in PV

Acute Lymphoblastic Leukemia: The Future of Treatment

OncLive houses thousands of videos that provide updates and information.
See more Videos

The Evolving Treatment Landscape of CLL

$Relapsed/Refractory CLL: Evaluating Other Novel Agents$

Relapsed/Refractory CLL: Evaluating Other Novel Agents

$Novel Approaches to Treating Relapsed/Refractory CLL$

Novel Approaches to Treating Relapsed/Refractory CLL

$Continuing Therapy in Relapsed/Refractory CLL$

$Evaluating Pharmacologic Agents in Relapsed/Refractory CLL$

CLL: Post-Ibrutinib or Chemoimmunotherapy Approaches

$Approaching Therapy for Relapsed/Refractory CLL$

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

2015 ASH Annual Meeting Highlights

Gina Columbus highlights findings from the 2015 American Society of Hematology Annual Meeting and Exposition, including advances in multiple myeloma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.View Now

Multiple Myeloma: Emerging Concepts in Management

This Peer Exchange discussion, moderated by A. Keith Stuart, MB, ChB, highlights the most up-to-date information available on the emerging concepts in the management of multiple myeloma. View Now

Featured Video

Immunotherapy in the Treatment of Follicular Lymphoma

Ian W. Flinn, MD, PhD; Grzegorz S. Nowakowski, MD; Loretta J. Nastoupil, MD; and Anas Younes, MD, reflect on the value of immunotherapy, immunotherapy combination strategies, and understanding the tumor microenvironment in treating follicular lymphoma.View now

FDA Approvals in Cervical Cancer, Ovarian Cancer, and CLL, and More